On September 14, 2026 Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1)-associated neurofibromas, reported it will present initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with NF1.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data will be presented at the 2026 European Neurofibromatosis Conference, taking place November 12–14, 2026, at the Hyatt Regency Vienna in Vienna, Austria, and will represent the Company’s first public disclosure of clinical data from Part A of the trial.

Details of the Oral Presentation:
Presenter: Rebecca Brown, MD, University of Alabama at Birmingham
Presentation Type: Oral Presentation
Session title: Clinical Session 3: Visible Manifestations in Neurofibromatosis
Session day and time: Friday, 13 November 2026, 08:00-09:30 (CET)
Room: Lecture Hall 1

Details of the Poster Presentation:
Presenter: Tiago Reis Marques, Pasithea Therapeutics Chief Executive Officer
Presentation Type: Poster
Poster Session: Thursday, November 12

The full presentations will be made available in accordance with the conference’s program schedule. The Company plans to issue a follow-up press release with detailed results at the time of presentation.

(Press release, Pasithea Therapeutics, SEP 14, 2026, View Source [SID1234670823])